{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T02:52:53Z","timestamp":1785207173439,"version":"3.55.0"},"reference-count":37,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,10,23]],"date-time":"2023-10-23T00:00:00Z","timestamp":1698019200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> Ondansetron is a selective antagonist of the serotonin 5-HT3 receptor that is commonly used to treat morning sickness. It is estimated that 70%\u201380% of pregnant women suffer from morning sickness, a condition characterized by nausea and vomiting. However, it is still controversial regarding its safety during pregnancy, and continued research will be necessary to fully understand the risks and benefits associated with its use. Therefore, we aimed to identify and provide details of the efficacy and safety of ondansetron in clinical trials.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> A search was conducted of the <jats:ext-link>ClinicalTrials.gov<\/jats:ext-link> database on 13 April 2023, using the search term \u201condansetron and pregnancy.\u201d Inclusion and exclusion criteria were defined to identify relevant clinical trials. The inclusion criteria encompassed clinical trials related to pregnancy that utilized ondansetron as a treatment, while other clinical trials were excluded from consideration. All data extractions such as study title, study status, study type, intervention details, and outcome were collected.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> A total of 18 clinical trials were identified, of which only 6 focused on studying the effects of ondansetron. Their respective study titles, statuses, conditions, interventions, outcome measures, and enrollment sizes have been written in detail. The information collected from these trials will contribute to our understanding of the potential benefits and risks of ondansetron in the context of pregnancy and its complications.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> Ondansetron has been shown to be an effective treatment for nausea and vomiting, including pregnancy-related morning sickness. Further research is needed to better understand the potential risks and benefits associated with its use in pregnant women.<\/jats:p><jats:p><jats:bold>Systematic Review Registration:<\/jats:bold><jats:ext-link>ClinicalTrials.gov<\/jats:ext-link>, identifier<\/jats:p>","DOI":"10.3389\/fphar.2023.1291235","type":"journal-article","created":{"date-parts":[[2023,10,23]],"date-time":"2023-10-23T07:23:15Z","timestamp":1698045795000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Efficacy and safety of ondansetron for morning sickness in pregnancy: a systematic review of clinical trials"],"prefix":"10.3389","volume":"14","author":[{"given":"Ahmed M.","family":"Ashour","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,10,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1097\/AOG.0000000000001388","article-title":"Ondansetron use in pregnancy and birth defects: a systematic review","volume":"127","author":"Carstairs","year":"2016","journal-title":"Obstetrics Gynecol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1007\/s00404-014-3572-2","article-title":"Plasma serotonin levels are elevated in pregnant women with hyperemesis gravidarum","volume":"291","author":"Cengiz","year":"2015","journal-title":"Archives Gynecol. obstetrics"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1097\/00000542-200506000-00006","article-title":"Prolongation of QTc interval after postoperative nausea and vomiting treatment by droperidol or ondansetron","volume":"102","author":"Charbit","year":"2005","journal-title":"J. Am. Soc. Anesthesiol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1517\/17425255.2014.882317","article-title":"Ondansetron: a review of pharmacokinetics and clinical experience in postoperative nausea and vomiting","volume":"10","author":"Christofaki","year":"2014","journal-title":"Expert Opin. Drug Metabolism Toxicol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1097\/ogx.0b013e3182a8784d","article-title":"The impact of nausea and vomiting of pregnancy on quality of life: report of a national consumer survey and recommendations for improving care","volume":"68","author":"Clark","year":"2013","journal-title":"Obstetrical Gynecol. Surv."},{"key":"B6","doi-asserted-by":"publisher","first-page":"909860","DOI":"10.1155\/2013\/909860","article-title":"Off-label use of ondansetron in pregnancy in Western Australia","volume":"2013","author":"Colvin","year":"2013","journal-title":"BioMed Res. Int."},{"key":"B7","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.reprotox.2014.10.017","article-title":"Use of ondansetron during pregnancy and congenital malformations in the infant","volume":"50","author":"Danielsson","year":"2014","journal-title":"Reprod. Toxicol."},{"key":"B8","doi-asserted-by":"crossref","first-page":"207","DOI":"10.4324\/9781315384801-16","article-title":"Complementary\/alternative medicine during pregnancy","volume-title":"Therapeutics in pregnancy and lactation","author":"Ernst","year":"2019"},{"key":"B9","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1038\/s41572-019-0110-3","article-title":"Nausea and vomiting of pregnancy and hyperemesis gravidarum","volume":"5","author":"Fejzo","year":"2019","journal-title":"Nat. Rev. Dis. Prim."},{"key":"B10","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.annemergmed.2013.10.026","article-title":"Ondansetron and the risk of cardiac arrhythmias: a systematic review and postmarketing analysis","volume":"64","author":"Freedman","year":"2014","journal-title":"Ann. Emerg. Med."},{"key":"B11","article-title":"Ondansetron","volume-title":"StatPearls","author":"Griddine","year":"2022"},{"key":"B12","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1097\/MCG.0000000000001485","article-title":"Nausea and vomiting in 2021: a comprehensive update","volume":"55","author":"Heckroth","year":"2021","journal-title":"J. Clin. gastroenterology"},{"key":"B13","doi-asserted-by":"publisher","first-page":"3240","DOI":"10.1200\/JCO.2017.74.4789","article-title":"Antiemetics: American Society of Clinical Oncology clinical practice guideline update","volume":"35","author":"Hesketh","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.reprotox.2019.03.001","article-title":"Use of ondansetron during pregnancy and the risk of major congenital malformations: a systematic review and meta-analysis","volume":"86","author":"Kaplan","year":"2019","journal-title":"Reprod. Toxicol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1177\/1753495X15621154","article-title":"Ondansetron and pregnancy: understanding the data","volume":"9","author":"Kennedy","year":"2016","journal-title":"Obstet. Med."},{"key":"B16","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1016\/j.ajog.2014.08.017","article-title":"Treating morning sickness in the United States: changes in prescribing are needed","volume":"211","author":"Koren","year":"2014","journal-title":"Am. J. Obstetrics Gynecol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.gtc.2011.03.009","article-title":"Nausea and vomiting of pregnancy","volume":"40","author":"Lee","year":"2011","journal-title":"Gastroenterol. Clin."},{"key":"B18","first-page":"56","article-title":"Mirtazapine and ondansetron: a dual pharmacodynamic and pharmacokinetic interaction","volume":"16","author":"Lozano","year":"2013","journal-title":"Afr. J. Psychiatry"},{"key":"B19","first-page":"e555","article-title":"Surviving morning sickness successfully: from patient\u2019s perception to rational management","volume":"21","author":"Maltepe","year":"2014","journal-title":"J. Popul. Ther. Clin. Pharmacol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1185\/030079907x167525","article-title":"Efficacy of dronabinol alone and in combination with ondansetron versus ondansetron alone for delayed chemotherapy-induced nausea and vomiting","volume":"23","author":"Meiri","year":"2007","journal-title":"Curr. Med. Res. Opin."},{"key":"B21","first-page":"3","volume-title":"Ondansetron for nausea and vomiting in pregnancy: re-evaluating the teratogenic risk","author":"Michie","year":"2020"},{"key":"B22","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1097\/AOG.0000000000002679","article-title":"Ondansetron for treatment of nausea and vomiting of pregnancy and the risk of specific birth defects","volume":"132","author":"Parker","year":"2018","journal-title":"Obstetrics Gynecol."},{"key":"B23","first-page":"121","article-title":"Nausea and vomiting of pregnancy","volume":"68","author":"Quinlan","year":"2003","journal-title":"Am. Fam. physician"},{"key":"B24","doi-asserted-by":"publisher","first-page":"95","DOI":"10.2165\/00003088-199529020-00004","article-title":"Ondansetron clinical pharmacokinetics","volume":"29","author":"Roila","year":"1995","journal-title":"Clin. Pharmacokinet."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1080\/17512433.2016.1190271","article-title":"Efficacy, safety and effectiveness of ondansetron compared to other serotonin-3 receptor antagonists (5-HT3RAs) used to control chemotherapy-induced nausea and vomiting: systematic review and meta-analysis","volume":"9","author":"Simino","year":"2016","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1111\/j.2042-7158.1996.tb03973.x","article-title":"Clinical pharmacokinetics of ondansetron. A review","volume":"48","author":"Simpson","year":"1996","journal-title":"J. Pharm. Pharmacol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"4526","DOI":"10.1111\/bcp.15370","article-title":"Ondansetron use in nausea and vomiting during pregnancy: a descriptive analysis of prescription patterns and patient characteristics in UK general practice","volume":"88","author":"Slattery","year":"2022","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"37","DOI":"10.52221\/nuri.v1i1.209","article-title":"Literature Review: herbs to prevent nausea and vomiting in pregnant women","volume":"1","author":"Solihah","year":"2023","journal-title":"Nurul Ilmi J. Health Sci. Midwifery"},{"key":"B29","unstructured":"NCT013573692016"},{"key":"B30","unstructured":"NCT014147772011"},{"key":"B31","unstructured":"NCT01668069"},{"key":"B32","unstructured":"NCT01801475"},{"key":"B33","unstructured":"NCT019657042020"},{"key":"B34","unstructured":"NCT037856912022"},{"key":"B35","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.biochi.2019.03.023","article-title":"Serotonin-estrogen interactions: what can we learn from pregnancy?","volume":"161","author":"Thibeault","year":"2019","journal-title":"Biochimie"},{"key":"B36","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1080\/030097400446625","article-title":"Preclinical and clinical pharmacology of the 5-HT3 receptor antagonists","volume":"29","author":"Wolf","year":"2000","journal-title":"Scand. J. Rheumatology"},{"key":"B37","doi-asserted-by":"publisher","first-page":"e0186006","DOI":"10.1371\/journal.pone.0186006","article-title":"Comparative efficacy of ramosetron and ondansetron in preventing postoperative nausea and vomiting: an updated systematic review and meta-analysis with trial sequential analysis","volume":"12","author":"Yokoi","year":"2017","journal-title":"PLOS ONE"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1291235\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,23]],"date-time":"2023-10-23T07:23:20Z","timestamp":1698045800000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1291235\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,23]]},"references-count":37,"alternative-id":["10.3389\/fphar.2023.1291235"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2023.1291235","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,23]]},"article-number":"1291235"}}